Pidilizumab in the treatment of diffuse large B-cell lymphoma

Expert Opinion on Biological Therapy

Volumn 14, Issue 9, 2014, Pages 1361-1368

  Bryan, Locke J ^a   Gordon, Leo I ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Diffuse large B cell lymphoma; Monoclonal antibody; Non Hodgkin lymphoma; Pidilizumab; Programmed death 1

Indexed keywords

ANTINEOPLASTIC AGENT; IMMUNOLOGICAL ADJUVANT; MONOCLONAL ANTIBODY; PDCD1 PROTEIN, HUMAN; PIDILIZUMAB; PROGRAMMED DEATH 1 RECEPTOR;

ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL (TOPIC); DISEASE FREE SURVIVAL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IMMUNOTHERAPY; LYMPHOMA, LARGE B-CELL, DIFFUSE; MOLECULARLY TARGETED THERAPY; PROCEDURES;

ADJUVANTS, IMMUNOLOGIC; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; DISEASE-FREE SURVIVAL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOTHERAPY; LYMPHOMA, LARGE B-CELL, DIFFUSE; MOLECULAR TARGETED THERAPY; PROGRAMMED CELL DEATH 1 RECEPTOR;

EID: 84905816355     PISSN: 14712598     EISSN: 17447682     Source Type: Journal    
DOI: 10.1517/14712598.2014.942637     Document Type: Review

References (28)

1. Ishida Y, Agata Y, Shibahara K, Honjo T. Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. EMBO J 1992;11(11):3887-95
2. Keir ME, Butte MJ, Freeman GJ, Sharpe AH. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol 2008;26:677-704
3. Quezada SA, Peggs KS. Exploiting CTLA-4, PD-1 and PD-L1 to reactivate the host immune response against cancer. Br J Cancer 2013;108(8):1560-5
4. Jacobsen ED. Restoring antitumor immunity via PD-1 blockade after autologous stem-cell transplantation for diffuse large B-cell lymphoma. J Clin Oncol 2014;31(33):4268-70
5. Hardy B, Yampolski I, Kovjazin R, et al. A monoclonal antibody against a human B lymphoblastoid cell line induces tumor regression in mice. Cancer Res 1994;54(22):5793-6
6. Hardy B, Kovjazin R, Raiter A, et al. A lymphocyte-Activating monoclonal antibody induces regression of human tumors in severe combined immunodeficient mice. Proc Natl Acad Sci USA 1997;94(11):5756-60
7. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project. Blood 1997;89(11):3909-18
8. Raiter A, Novogrodsky A, Hardy B. Activation of lymphocytes by BAT and anti CTLA-4: Comparison of binding to T and B cells. Immunol Lett 1999;69(2):247-51
9. Berger R, Rotem-Yehudar R, Slama G, et al. Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies. Clin Cancer Res 2008;14(10):3044-51
10. Armand P, Nagler A, Weller EA, et al. Disabling immune tolerance by programmed death-1 blockade with pidilizumab after autologous hematopoietic stem-cell transplantation for diffuse large B-cell lymphoma: Results of an international phase II trial. J Clin Oncol 2013;31(33):4199-206
11. Armand P, Welch S, Kim HT, et al. Prognostic factors for patients with diffuse large B cell lymphoma and transformed indolent lymphoma undergoing autologous stem cell transplantation in the positron emission tomography era. Br J Haematol 2013;160(5):608-17
12. Westin JR, Chu F, Zhang M, et al. Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: A single group, open-label, phase 2 trial. Lancet Oncol 2014;15(1):69-77
13. Shimauchi T, Kabashima K, Nakashima D, et al. Augmented expression of programmed death-1 in both neoplastic and non-neoplastic CD4+ T-cells in adult T-cell leukemia/lymphoma. Int J Cancer 2007;121(12):2585-90
14. Xerri L, Chetaille B, Serriari N, et al. Programmed death 1 is a marker of angioimmunoblastic T-cell lymphoma and B-cell small lymphocytic lymphoma/chronic lymphocytic leukemia. Hum Pathol 2008;39(7):1050-8
15. Wang L, Qian J, Lu Y, et al. Immune evasion of mantle cell lymphoma: Expression of B7-H1 leads to inhibited T-cell response to and killing of tumor cells. Haematologica 2013;98(9):1458-66
16. Muenst S, Hoeller S, Willi N, et al. Diagnostic and prognostic utility of PD-1 in B cell lymphomas. Dis Markers 2010;29(1):47-53
17. Carreras J, Lopez-Guillermo A, Roncador G, et al. High numbers of tumor-infiltrating programmed cell death 1-positive regulatory lymphocytes are associated with improved overall survival in follicular lymphoma. J Clin Oncol 2009;27(9):1470-6
18. Cotta CV, Coleman JF, Li S, Hsi ED. Nodular lymphocyte predominant Hodgkin lymphoma and diffuse large B-cell lymphoma: A study of six cases concurrently involving the same site. Histopathology 2011;59(6):1194-203
19. Muenst S, Hoeller S, Dirnhofer S, Tzankov A. Increased programmed death-1+ tumor-infiltrating lymphocytes in classical Hodgkin lymphoma substantiate reduced overall survival. Hum Pathol 2009;40(12):1715-22
20. Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000;403(6769):503-11
21. Rosenwald A, Wright G, Leroy K, et al. Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma. J Exp Med 2003;198(6):851-62
22. Roschewski M, Staudt LM, Wilson WH. Diffuse large B-cell lymphoma-Treatment approaches in the molecular era. Nat Rev Clin Oncol 2014;11(1):12-23
23. Dorfman DM, Brown JA, Shahsafaei A, Freeman GJ. Programmed death-1(PD-1) is a marker of germinal center-Associated T cells and angioimmunoblastic T-cell lymphoma. Am J Surg Pathol 2006;30(7):802-10
24. Andorsky DJ, Yamada RE, Said J, et al. Programmed death ligand 1 is expressed by non-hodgkin lymphomas and inhibits the activity of tumorassociated T cells. Clin Cancer Res 2011;17(13):4232-44
25. Chen BJ, Chapuy B, Ouyang J, et al. PD-L1 expression is characteristic of a subset of aggressive B-cell lymphomas and virus-Associated malignancies. Clin Cancer Res 2013;19(13):3462-73
26. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012;12(4):252-64
27. Yang Z-Z, Grote D, Ziesmer S, Ansell S. PD-1 expression defines two distinct T-Cell subpopulations that differentially impact patient outcomes in Follicular Lymphoma. ASH 55th Annual Meeting 2013; New Orleans, LA; 2013
28. Fest T, Rosille D, Gressier M, et al. Blood soluble PD-L1 protein in aggressive diffuse large B-cell lymphoma impacts patient's overall survival. 55th ASH Annual Meeting 2013; New Orleans, LA; 2013